McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015;19:223–38.

Article  PubMed  PubMed Central  Google Scholar 

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–14.

Article  PubMed  Google Scholar 

Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg. 2011;253:745–58.

Article  PubMed  Google Scholar 

Harlan LC, Parsons HM, Wiggins CL, Stevens JL, Patt YZ. Treatment of hepatocellular carcinoma in the community: disparities in standard therapy. Liver Cancer. 2015;4:70–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mu C, Wang XL, Ruan Y, Sun JJ, Hu XR, Cheng Y. Recent advances in the contribution of circRNAs to cisplatin chemotherapy resistance in cancers. Neoplasma. 2021;68:1119–31.

Article  CAS  PubMed  Google Scholar 

Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869–83.

Article  CAS  PubMed  Google Scholar 

Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016;106:27–36.

Article  CAS  PubMed  Google Scholar 

Lai GM, Ozols RF, Smyth JF, Young RC, Hamilton TC. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol. 1988;37:4597–600.

Article  CAS  PubMed  Google Scholar 

Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18:610–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang X, Wang Y, A G, Qu C, Chen J. Pan-cancer analysis of PARP1 alterations as biomarkers in the prediction of immunotherapeutic effects and the association of its expression levels and immunotherapy signatures. Front Immunol. 2021;12:721030.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun C, Jing W, Xiong G, Ma D, Lin Y, Lv X, et al. Inhibiting Src-mediated PARP1 tyrosine phosphorylation confers synthetic lethality to PARP1 inhibition in HCC. Cancer Lett. 2022;526:180–92.

Article  CAS  PubMed  Google Scholar 

Singh MP, Cho HJ, Kim JT, Baek KE, Lee HG, Kang SC. Morin hydrate reverses cisplatin resistance by impairing PARP1/HMGB1-dependent autophagy in hepatocellular carcinoma. Cancers. 2019;11:986.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chiappa M, Guffanti F, Bertoni F, Colombo I, Damia G. Overcoming PARPi resistance: preclinical and clinical evidence in ovarian cancer. Drug Resist Updat. 2021;55:100744.

Article  CAS  PubMed  Google Scholar 

Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–34.

Article  CAS  PubMed  Google Scholar 

Wang S, Han L, Han J, Li P, Ding Q, Zhang QJ, et al. Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation. Nat Chem Biol. 2019;15:1223–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Fang R, Cui M, Zhang W, Bai X, Wang H, et al. The oncoprotein HBXIP up-regulates YAP through activation of transcription factor c-Myb to promote growth of liver cancer. Cancer Lett. 2017;385:234–42.

Article  CAS  PubMed  Google Scholar 

Zou W, Ma X, Yang H, Hua W, Chen B, Cai G. Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer. Exp Biol Med. 2017;242:497–504.

Article  CAS  Google Scholar 

Cai X, Wang X, Cao C, Gao Y, Zhang S, Yang Z, et al. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g. Cancer Lett. 2018;415:11–9.

Article  CAS  PubMed  Google Scholar 

Fei H, Zhou Y, Li R, Yang M, Ma J, Wang F. HBXIP, a binding protein of HBx, regulates maintenance of the G2/M phase checkpoint induced by DNA damage and enhances sensitivity to doxorubicin-induced cytotoxicity. Cell Cycle. 2017;16:468–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grancher A, Michel P, Di Fiore F, Sefrioui D. Colorectal cancer chemoprevention: is aspirin still in the game? Cancer Biol Ther. 2022;23:446–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu B, Wang T, Wang H, Zhang L, Xu F, Fang R, et al. Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer. J Hematol Oncol. 2018;11:26.

Article  PubMed  PubMed Central  Google Scholar 

Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–79.

Article  CAS  PubMed  Google Scholar 

Wu X, Dong Z, Wang CJ, Barlow LJ, Fako V, Serrano MA, et al. FASN regulates cellular response to genotoxic treatments by increasing PARP-1 expression and DNA repair activity via NF-κB and SP1. Proc Natl Acad Sci USA. 2016;113:E6965–e73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Res. 2013;73:2271–80.

Article  CAS  PubMed  Google Scholar 

Kothandapani A, Sawant A, Dangeti VS, Sobol RW, Patrick SM. Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity. Nucleic Acids Res. 2013;41:7332–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roundtree IA, Evans ME, Pan T, He C. Dynamic RNA modifications in gene expression regulation. Cell. 2017;169:1187–200.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang N, Wang T, Li Q, Han F, Wang Z, Zhu R, et al. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α. J Cell Physiol. 2021;236:3863–80.

Article  CAS  PubMed  Google Scholar 

Pan C, Kang J, Hwang JS, Li J, Boese AC, Wang X, et al. Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1. Nat Commun. 2021;12:4960.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Y, Jing X, Hu K, Wen X, Ye L, Zhang X, et al. The c-MYC-WDR43 signalling axis promo